Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era

An analysis from the FOLL05 trial of the Fondazione Italiana Linfomi

Luigi Marcheselli, Alessia Bari, Antonella Anastasia, Barbara Botto, Benedetta Puccini, Alessandra Dondi, Angelo M. Carella, Isabel Alvarez, Annalisa Chiarenza, Annalisa Arcari, Flavia Salvi, Massimo Federico

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Recently, in an attempt to improve the discrimination power of the international prognostic index (IPI), patients with diffuse large B-cell lymphoma were evaluated to determine the prognostic roles of peripheral blood absolute monocyte count (AMC) and absolute lymphocyte count (ALC). Here, we analysed data of 428 patients with follicular lymphoma (FL) enrolled in a prospective, randomized trial (FOLL05 study) conducted by Fondazione Italiana Linfomi, to assess the impact of AMC and ALC on progression-free survival (PFS). All patients had been treated with one of three treatment combinations: (i) rituximab (R) plus cyclophosphamide, vincristine and prednisone; (ii) R plus cyclophosphamide, doxorubicin, vincristine and prednisone or (iii) R plus mitoxantrone and fludarabine. We showed that only AMC was a powerful predictor of PFS, and possibly overall survival, in patients with FL treated with combination chemotherapy regimens that contained R. The AMC can be used alone as a novel, simple factor that can predict survival outcome in patients with FL, independent of the immunochemotherapy regimen. It may therefore be widely used by clinicians, due to its simplicity and broad applicability. Additionally, it can be combined with other factors that determine the IPI or FLIPI, to increase the discriminating ability of these indices.

Original languageEnglish
Pages (from-to)544-551
Number of pages8
JournalBritish Journal of Haematology
Volume169
Issue number4
DOIs
Publication statusPublished - May 1 2015

Fingerprint

Follicular Lymphoma
Lymphocyte Count
Monocytes
Vincristine
Prednisone
Cyclophosphamide
Disease-Free Survival
Mitoxantrone
Survival
Lymphoma, Large B-Cell, Diffuse
Combination Drug Therapy
Doxorubicin
Rituximab

Keywords

  • Lymphocytes
  • Monocytes
  • Non-Hodgkin lymphoma
  • Prognostic

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era : An analysis from the FOLL05 trial of the Fondazione Italiana Linfomi. / Marcheselli, Luigi; Bari, Alessia; Anastasia, Antonella; Botto, Barbara; Puccini, Benedetta; Dondi, Alessandra; Carella, Angelo M.; Alvarez, Isabel; Chiarenza, Annalisa; Arcari, Annalisa; Salvi, Flavia; Federico, Massimo.

In: British Journal of Haematology, Vol. 169, No. 4, 01.05.2015, p. 544-551.

Research output: Contribution to journalArticle

Marcheselli, Luigi ; Bari, Alessia ; Anastasia, Antonella ; Botto, Barbara ; Puccini, Benedetta ; Dondi, Alessandra ; Carella, Angelo M. ; Alvarez, Isabel ; Chiarenza, Annalisa ; Arcari, Annalisa ; Salvi, Flavia ; Federico, Massimo. / Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era : An analysis from the FOLL05 trial of the Fondazione Italiana Linfomi. In: British Journal of Haematology. 2015 ; Vol. 169, No. 4. pp. 544-551.
@article{0319092691e7470dbd311eea231855f2,
title = "Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: An analysis from the FOLL05 trial of the Fondazione Italiana Linfomi",
abstract = "Recently, in an attempt to improve the discrimination power of the international prognostic index (IPI), patients with diffuse large B-cell lymphoma were evaluated to determine the prognostic roles of peripheral blood absolute monocyte count (AMC) and absolute lymphocyte count (ALC). Here, we analysed data of 428 patients with follicular lymphoma (FL) enrolled in a prospective, randomized trial (FOLL05 study) conducted by Fondazione Italiana Linfomi, to assess the impact of AMC and ALC on progression-free survival (PFS). All patients had been treated with one of three treatment combinations: (i) rituximab (R) plus cyclophosphamide, vincristine and prednisone; (ii) R plus cyclophosphamide, doxorubicin, vincristine and prednisone or (iii) R plus mitoxantrone and fludarabine. We showed that only AMC was a powerful predictor of PFS, and possibly overall survival, in patients with FL treated with combination chemotherapy regimens that contained R. The AMC can be used alone as a novel, simple factor that can predict survival outcome in patients with FL, independent of the immunochemotherapy regimen. It may therefore be widely used by clinicians, due to its simplicity and broad applicability. Additionally, it can be combined with other factors that determine the IPI or FLIPI, to increase the discriminating ability of these indices.",
keywords = "Lymphocytes, Monocytes, Non-Hodgkin lymphoma, Prognostic",
author = "Luigi Marcheselli and Alessia Bari and Antonella Anastasia and Barbara Botto and Benedetta Puccini and Alessandra Dondi and Carella, {Angelo M.} and Isabel Alvarez and Annalisa Chiarenza and Annalisa Arcari and Flavia Salvi and Massimo Federico",
year = "2015",
month = "5",
day = "1",
doi = "10.1111/bjh.13332",
language = "English",
volume = "169",
pages = "544--551",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "4",

}

TY - JOUR

T1 - Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era

T2 - An analysis from the FOLL05 trial of the Fondazione Italiana Linfomi

AU - Marcheselli, Luigi

AU - Bari, Alessia

AU - Anastasia, Antonella

AU - Botto, Barbara

AU - Puccini, Benedetta

AU - Dondi, Alessandra

AU - Carella, Angelo M.

AU - Alvarez, Isabel

AU - Chiarenza, Annalisa

AU - Arcari, Annalisa

AU - Salvi, Flavia

AU - Federico, Massimo

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Recently, in an attempt to improve the discrimination power of the international prognostic index (IPI), patients with diffuse large B-cell lymphoma were evaluated to determine the prognostic roles of peripheral blood absolute monocyte count (AMC) and absolute lymphocyte count (ALC). Here, we analysed data of 428 patients with follicular lymphoma (FL) enrolled in a prospective, randomized trial (FOLL05 study) conducted by Fondazione Italiana Linfomi, to assess the impact of AMC and ALC on progression-free survival (PFS). All patients had been treated with one of three treatment combinations: (i) rituximab (R) plus cyclophosphamide, vincristine and prednisone; (ii) R plus cyclophosphamide, doxorubicin, vincristine and prednisone or (iii) R plus mitoxantrone and fludarabine. We showed that only AMC was a powerful predictor of PFS, and possibly overall survival, in patients with FL treated with combination chemotherapy regimens that contained R. The AMC can be used alone as a novel, simple factor that can predict survival outcome in patients with FL, independent of the immunochemotherapy regimen. It may therefore be widely used by clinicians, due to its simplicity and broad applicability. Additionally, it can be combined with other factors that determine the IPI or FLIPI, to increase the discriminating ability of these indices.

AB - Recently, in an attempt to improve the discrimination power of the international prognostic index (IPI), patients with diffuse large B-cell lymphoma were evaluated to determine the prognostic roles of peripheral blood absolute monocyte count (AMC) and absolute lymphocyte count (ALC). Here, we analysed data of 428 patients with follicular lymphoma (FL) enrolled in a prospective, randomized trial (FOLL05 study) conducted by Fondazione Italiana Linfomi, to assess the impact of AMC and ALC on progression-free survival (PFS). All patients had been treated with one of three treatment combinations: (i) rituximab (R) plus cyclophosphamide, vincristine and prednisone; (ii) R plus cyclophosphamide, doxorubicin, vincristine and prednisone or (iii) R plus mitoxantrone and fludarabine. We showed that only AMC was a powerful predictor of PFS, and possibly overall survival, in patients with FL treated with combination chemotherapy regimens that contained R. The AMC can be used alone as a novel, simple factor that can predict survival outcome in patients with FL, independent of the immunochemotherapy regimen. It may therefore be widely used by clinicians, due to its simplicity and broad applicability. Additionally, it can be combined with other factors that determine the IPI or FLIPI, to increase the discriminating ability of these indices.

KW - Lymphocytes

KW - Monocytes

KW - Non-Hodgkin lymphoma

KW - Prognostic

UR - http://www.scopus.com/inward/record.url?scp=84928402492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928402492&partnerID=8YFLogxK

U2 - 10.1111/bjh.13332

DO - 10.1111/bjh.13332

M3 - Article

VL - 169

SP - 544

EP - 551

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 4

ER -